AFMD - アフィメド (Affimed N.V.) アフィメド



symbol AFMD
会社名 Affimed N.V. (アフィメド)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes FM13 AFM11 AFM21 AFM22 AFM24 TandAb and Trispecific Abs. It has started recruitment for Phase IIa clinical trial of AFM13 in patients with Hodgkin Lymphoma. It has initiated a Phase I clinical trial of AFM11 in patients with non-Hodgkin Lymphoma. AFM21 is in preclinical development. AFM22 which is an Epidermal Growth Factor Receptor variant III (EGFRvIII)/CD16A NK-cell TandAb is in preclinical development. AFM24 is an additional CD16A NK-cell TandAb targeting a validated solid tumor target EGFR-wild type. It is developing Trispecific Abs for treating multiple myeloma and CD33/CD3-specific T-cell TandAb to treat acute myeloid leukemia.   アフィメドはドイツのバイオ医薬品会社の持株会社。同社は2000年設立。ハイデルベルクのドイツがん研究センタ―で開発された技術をもとに、腫瘍細胞への自己免疫力を高める革新的なアプロ―チによるがん治療法の研究、開発、商品化に従事。開発中の製品にAFM13、AFM11、AFM21を含む。   
本社所在地 Technologiepark Im Neuenheimer Feld 582 Heidelberg 69120 DEU
代表者氏名 Thomas Hecht トーマス・ヘクト
代表者役職名 Chairman of the Supervisory Board
電話番号 +49 6221-67-4360
設立年月日 41760
市場名 NASDAQ National Market System
ipoyear 2014年
EBITDA EBITDA(百万ドル) -34.24747
終値(lastsale) 4.62
時価総額(marketcap) 288242114.16
時価総額 時価総額(百万ドル) 218.36520
売上高 売上高(百万ドル) 2.05078
企業価値(EV) 企業価値(EV)(百万ドル) 170.73193
当期純利益 当期純利益(百万ドル) -35.31480
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Affimed NV revenues decreased 25% to EUR682K. Net loss increased 3% to EUR16.2M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development expenses - Bala increase of 23% to EUR13.1M (expense) Interest Expense Net increase from EUR168K to EUR466K (expense).


 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アフィメド AFMD Affimed N.V.)

 twitter  (公式ツイッターやCEOツイッターなど)